NEW YORK, June 4, 2017 – Y-mAbs Therapeutics, Inc. (YmAbs), an immunotherapy company discovering and developing innovative treatments for patients with cancer, today announced positive top line results from a pivotal study of 131I-burtomab in Refractory Leptomeningeal Metastasis from Neuroblastoma. Results showed a 58 months average survival for the patients treated with 131I-burtomab in the study, compared to an average of 4.7 month and no long term survival or cure, for a contemporary cohort in the Central German Childhood Cancer Registry. After more than a decade of follow-up, data shows more than 40% overall long term survival indicating that the treated children have been cured.
At ASCO, Dr. Kim Kramer from Memorial Sloan Kettering Cancer Center (MSK) presented the overall survival data from 80 pediatric patients with CNS and leptomeningeal metastasis from neuroblastoma treated at MSK with 131I-burtomab, and Prof. Dr. med. Frank Berthold from the University of Cologne presented comparable historical data from the Central German Childhood Cancer Registry, thereby demonstrating that the use of 131I-burtomab led to a multi-fold increase of the average survival in this patient population, where no other established therapy exists.
YmAbs Founder, President and Head of Business Development and Strategy, Thomas Gad said, “Having witnessed this out-patient treatment first hand as a parent, these data provide a potential curative treatment addressing an unmet medical need for a life-threatening disease to children suffering from Refractory Leptomeningeal Metastasis from Neuroblastoma. YmAbs is now positioned to seek the most efficient route to approval. This could be a potential game changer for pediatric patients and their families.”
Dr. Claus Møller, Chief Executive Officer further notes, “In a setting, where no other therapies are approved, this survival data represents a true breakthrough and hope for these children.”
YmAbs is a clinical stage biopharmaceutical company focused on developing new cancer treatments through immunotherapies. In addition, YmAbs utilizes its platform technologies to create next-generation humanized, affinity matured bispecific antibodies targeting GD2 and B7-H3. To further improve our bispecific antibodies, we are collaborating with MSK on the development of a novel human protein tag that dimerizes T-cell engaging bispecific antibodies, which enables higher tumor binding and results in a longer serum half-life and a significantly greater T-cell mediated killing of tumor cells. Our treatments could potentially reduce longer-term toxicities associated with current chemotherapeutics and provide the potential for curative therapy even for patients with widespread disease. YmAbs’ goal is to drive multiple product candidates in select solid tumor cancers to FDA licensure. Each candidate has the potential to treat a variety of high-risk cancers.
To learn more, visit www.ymabs.com.
Y-mAbs Therapeutics, Inc.
Y-mabs Therapeutics, Inc.
750 Third Avenue, 9th Floor
New York, NY 10017
+1 212 847 9844
Y-mAbs Therapeutics A/S
Rungsted Strandvej 113
2960 Rungsted Kyst
+45 70 26 14 14